Bioluminescence Ventures

GEMMABio is a therapeutics company dedicated to developing gene therapies for individuals with rare diseases. Its mission is to accelerate research and enhance global access to these life-changing treatments, aiming to bring gene therapy discoveries from the lab to patients worldwide more swiftly and affordably.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Nido Biosciences, Inc., incorporated in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company employs a functional genomics discovery platform utilizing human cell lines to identify novel therapeutic targets for various neuromuscular and neurodegenerative conditions. By leveraging advances in neuroscience and human genetics, Nido Biosciences aims to create precise medications that address the underlying biology of these diseases, ultimately restoring healthy cell function and improving patient outcomes.